Skip to content
Science & Innovation
Patrick Thiaville, Ph.D
Breaking paradigms with continuous RNA manufacturing.
Enabling therapeutics and vaccines for all.
No scale up from pre-clinical to commercial.
>2x faster and > 2x lower COGs.
Increased quality and yield vs. industry standards.